Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04

Rhea-AI Filing Summary

Daniel Barber, President and CEO of Aquestive Therapeutics, sold a total of 25,000 shares of common stock in open-market or private transactions on July 15–16, 2026, at prices between $4.00 and $4.04 per share, under a Rule 10b5-1 trading plan, and now directly holds 610,574 shares.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares ($100,192)

Net Sell 2 txns

Insider Barber Daniel

Role President and CEO

Sold 25,000 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,369	$4.0016	$82K
Sale	Common Stock	4,631	$4.0344	$19K

Holdings After Transaction: Common Stock — 610,574 shares (Direct)

Footnotes (1)

1. The reported transaction involves sale transactions from $4.00 to $4.04 per share. The weighted average price per share was $4.0344. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price. The reported transaction involves sale transactions from $4.00 to $4.01 per share. The weighted average price per share was $4.00016. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Key Figures

Shares sold 2026-07-15: 4,631 shares Weighted average price 2026-07-15: $4.0344 per share Shares sold 2026-07-16: 20,369 shares +3 more

6 metrics

Shares sold 2026-07-15 4,631 shares Common stock sold by CEO Daniel Barber on 2026-07-15

Weighted average price 2026-07-15 $4.0344 per share Sale transactions from $4.00 to $4.04 per share

Shares sold 2026-07-16 20,369 shares Common stock sold by CEO Daniel Barber on 2026-07-16

Price range 2026-07-16 sale $4.00 to $4.01 per share Sale transactions from $4.00 to $4.01 per share

Total shares sold 25,000 shares Aggregate shares sold across both reported transactions

Shares held after transactions 610,574 shares Direct common stock holdings after 2026-07-16 sale

Key Terms

weighted average price per share, open market or private transaction, security holder

3 terms

weighted average price per share financial

"The weighted average price per share was $4.0344."

open market or private transaction regulatory

"Sale in open market or private transaction"

security holder regulatory

"the Issuer or a security holder of the Issuer, information"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 01:15 PM Accepted by SEC EDGAR 07/17/2026 - 01:15 PM Learn about SEC filing dates

FAQ

What insider transaction did Aquestive Therapeutics (AQST) report for Daniel Barber?

Aquestive Therapeutics (AQST) reported that President and CEO Daniel Barber sold 25,000 shares of common stock on July 15–16, 2026. The transactions were executed at prices between $4.00 and $4.04 per share under a Rule 10b5-1 trading plan, leaving him with 610,574 shares directly owned.

How many AQST shares did CEO Daniel Barber sell in this Form 4 filing?

CEO Daniel Barber sold a total of 25,000 AQST shares. This consisted of 4,631 shares sold on 2026-07-15 and 20,369 shares sold on 2026-07-16, as reported in two separate open-market or private sale transactions.

At what prices were the AQST shares sold by CEO Daniel Barber?

On 2026-07-15, Barber sold shares in transactions from $4.00 to $4.04 per share, with a weighted average of $4.0344. On 2026-07-16, he sold additional shares from $4.00 to $4.01 per share, with a reported weighted average of $4.00016.

How many Aquestive Therapeutics (AQST) shares does CEO Daniel Barber hold after the sales?

After these transactions, Daniel Barber directly owns 610,574 shares of Aquestive Therapeutics common stock. The Form 4 shows this holding level following the 20,369-share sale reported on 2026-07-16, which was the later of the two disclosed sale dates.

Were Daniel Barber’s AQST stock sales made under a Rule 10b5-1 trading plan?

Yes. The filing indicates the transactions were made under a Rule 10b5-1 trading plan. This means the 25,000-share sale sequence on July 15–16, 2026 was executed pursuant to a pre-established trading arrangement, rather than discretionary same-day trading decisions.

What types of transactions did the AQST CEO use to sell his shares?

The Form 4 classifies both transactions as sales of common stock in an “open market or private transaction.” These were non-derivative stock sales, not option exercises or conversions, and together reduced Daniel Barber’s direct holdings by 25,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		S		4,631	D	$4.0344(1)	630,943	D
Common Stock	07/16/2026		S		20,369	D	$4.0016(2)	610,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves sale transactions from $4.00 to $4.04 per share. The weighted average price per share was $4.0344. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

2. The reported transaction involves sale transactions from $4.00 to $4.01 per share. The weighted average price per share was $4.00016. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)